At the 75th American Heart Association's Scientific Sessions in Chicago, CV Therapeutics Inc. presented data from a Phase III trial of a drug that exceeded the company's expectations in its ability to convert an abnormally rapid heart rhythm back to normal. (BioWorld Today)